Wednesday 12 Mar, 2025 07:30 PM
Site map | Locate Us | Login
   PB Fintech drops on plan to inject Rs 696 crore into healthcare arm    Aptus Value allots 10-year NCDs worth Rs 200 cr    Paradeep Phosphates shuts Goa plants due to compressor breakdown    Emerald Finance gains after tieup with H.K. Jewels    Firstsource Solutions Ltd leads losers in 'A' group    TCS expands partnership with Coop Danmark to support operations and customer experience    K&R Rail Engineering Ltd leads losers in 'B' group    TechNVision Ventures jumps 27% in six days    Volumes soar at Gujarat State Petronet Ltd counter    Information Technology stocks edge lower    Acuit' Ratings upgrades ratings of Andrew Yule & Co. to 'B' with 'stable' outlook    Zydus Life gets US FDA nod for UTI treatment drug Methenamine    IDFC First Bank Ltd eases for fifth straight session    Sun Pharmaceuticals Industries Ltd rises for third straight session    Siyaram Recycling Industries bags Rs 5-cr purchase order 
Saravan Stocks
       
Hot Pursuit
Scrips, which has significant changes during the market hours.
Zydus Life gets US FDA nod for UTI treatment drug Methenamine
12-Mar-25   13:32 Hrs IST

The approved ANDA is a generic version of the US reference listed drug (USRLD) Hiprex Tablets.

Methenamine Hippurate tablets are indicated for prophylactic or suppressive treatment of frequently recurring urinary tract infections when long-term therapy is considered necessary.

Methenamine Hippurate tablets will be produced at Zydus Lifesciences Ltd (SEZ), Ahmedabad.

Methenamine Hippurate tablets had annual sales of $32.6 million in the United States (IQVIA MAT January 2025).

The group now has 419 approvals and has so far filed 483 ANDAs since the commencement of the filing process in FY 2003-04.

Zydus Lifesciences is a discovery-driven, global life sciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies.

The company reported a 29.62% jump in consolidated net profit of Rs 1,023.5 crore in Q3 FY25 compared with Rs 789.6 crore in Q3 FY24. Revenue from operations increased 16.96% YoY to Rs 5,269.1 crore during the quarter.

The scrip fell 1.73% to currently trade at Rs 884.35 on the BSE.

Powered by Capital Market - Live News
   Attention Investors : Prevent Unauthorized Transactions in your demat account --> Update your Mobile Number with your Depository Participant. Receive alerts on your Registered Mobile for all debit and other important transactions in your demat account directly from CDSL on the same day........issued in the interest of investors.
   Attention Investors : Prevent unauthorised transactions in your account Update your mobile numbers/email IDs with your stock brokers / Depository Participant. Receive information of your transactions directly from Exchange / Depositories on your mobile / email at the end of the day .... Issued in the interest of Investors.
   Attention Investors : KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
   Attention Investors : No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."
Email ID: info@ssplwealth.com       Customers grievances : grievances@ssplwealth.com     Compliance officer : Mr.R Udayakumar , compliance@ssplwealth.com,  Mobile No: 7305522205
Investor Charter | Annual Return | Account Closure | RE-KYC | Disclaimer | Feed Back | Privacy Policy | Policies & Procedures | |Rights & Obligations-English| Rights & Obligations-தமிழ் | Anti Money Laundering Policy | E-Voting | CSR | Voluntary Freezing / Blocking Hit Count : 39459557
Useful Links : NSE | BSE | MCX | NSDL | CDSL | SEBI | RBI | ATTENTION INVESTOR| SMART ODR
SEBI Regn.Nos : NSE/BSE-INZ000192638 | CDSL : IN-DP-262-2016
Member IDs : NSE : 11221 | BSE : 6292 | CDSL : 12045000 | MCX : 56990 | AMFI Regn.No : 2662
Designed , Developed & Content provided by CMOTS INFOTECH.(ISO 9001:2015 certified) © Copyright 2011 All Rights Reserved. SSPL WEALTH Pvt. Ltd